Beacon Therapeutics

aid: beacon-therapeutics
name: Beacon Therapeutics
description: Beacon Therapeutics is a clinical-stage ophthalmic gene therapy company founded in 2023 to save and restore the
  sight of people living with rare and prevalent retinal diseases that lead to blindness. Built around adeno-associated virus
  (AAV) gene therapy, the company delivers functional copies of mutated genes into retinal cells so the body can produce the
  missing therapeutic protein. Its lead clinical program, laru-zova (laruparetigene zovaparvovec), targets X-linked retinitis
  pigmentosa (XLRP), alongside preclinical programs in dry age-related macular degeneration (dAMD) and cone-rod dystrophy
  (CRD), the latter in-licensed from the University of Oxford. Beacon operates across the United Kingdom and the United States,
  with a corporate base in London and a US presence in the Cambridge, Massachusetts area. It is a therapeutics developer,
  not a software or data platform company, and publishes no public API, SDK or developer program.
deliveryModel:
  model: unknown
  open_source: false
  commercial: false
  callable_host: false
  label: Delivery model not determined — needs a product licence on record
  confidence: low
  source:
  - none
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  probe_state: none
  source:
  - security
  generated: '2026-11-06'
  method: derived
image: https://www.beacontx.com/wp-content/themes/beacon/assets/images/favicon/apple-touch-icon.png
url: https://raw.githubusercontent.com/api-evangelist/beacon-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.23'
created: '2026-08-06'
modified: '2026-08-06'
tags:
- Company
- Biotechnology
- Gene Therapy
- Ophthalmology
- Clinical Trials
- Life Sciences
- Rare Disease
- Pharmaceuticals
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://www.beacontx.com/
- type: About
  url: https://www.beacontx.com/about-us/
- type: Blog
  url: https://www.beacontx.com/news-and-events/
- type: BlogRSS
  url: https://www.beacontx.com/feed/
- type: Contact
  url: https://www.beacontx.com/contact/
- type: PrivacyPolicy
  url: https://www.beacontx.com/privacy-statement/
- type: Careers
  url: https://www.beacontx.com/careers/
- type: DomainSecurity
  url: security/beacon-therapeutics-domain-security.yml
x-enrichment:
  date: '2026-08-06'
  status: minimal
  artifacts_added: 1
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Beacon Therapeutics is a clinical-stage AAV gene therapy developer whose entire public surface is a 14-page WordPress
    marketing site (pipeline, clinical trials, disease focus, careers) — /developers, /api, /openapi.json, /llms.txt and every
    /.well-known/ path return a hard 404, and the product is a retinal therapeutic, not software.
  evidence:
  - url: https://www.beacontx.com/developers
    status: 404
  - url: https://www.beacontx.com/openapi.json
    status: 404
  - url: https://www.beacontx.com/.well-known/agent-card.json
    status: 404
  - url: https://www.beacontx.com/.well-known/security.txt
    status: 404
  - url: https://www.beacontx.com/llms.txt
    status: 404
  - url: https://www.beacontx.com/sitemap_index.xml
    status: 200
  checked: '2026-08-06'